Radiant Innovation Inc.

Radiant Innovation Inc.

TTPEX:3373
16.20
TWD
-0.25
(-1.52%)
-0.74EPS
788.09MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18.1
18.91
19.22
17.39
16.2
17.12
16.48
54.95
20.69
11.86
8.79
8.83
8.14
8.65
Basic EPS, GAAP
0.42
0.93
1.47
0.76
0.28
0.3
0.6
15.46
2.36
0.6
-1.02
-0.6
-1.27
-0.74
Free Cash Flow per Basic Share
0.31
-0.71
-1.29
1.28
-0.82
0.01
1.3
15.69
-3.3
-0.93
-0.1
0.15
-0.11
-0.07
Dividend per Share
- -
0.11
0.64
1.27
0.45
0.27
0.45
1.82
9.09
1.36
0.45
0.91
- -
- -
Book Value per Share
11.85
14.89
15.54
14.41
14.07
13.99
13.83
28.28
22.42
21.45
19.45
18.18
16.67
16.53
Tangible Book Value per Share
11.59
14.68
15.15
14.17
13.96
13.87
13.79
28.22
22.28
21.36
19.29
18.13
16.65
16.51
Basic Weighted Avg Shares
37
39
48
48
48
48
48
48
48
48
48
48
48
47
Sales/Revenue/Turnover
663
741
915
828
771
815
785
2,617
985
565
418
421
388
409
Operating Margin (%)
1.37
3.9
7.05
6.2
4.25
1.29
3.85
36.35
15.17
-2.69
-18.2
-14
-18.15
-15.17
Depreciation Expense
22
20
25
29
23
22
24
22
28
30
33
30
23
21
Net Income, GAAP
15
36
70
36
13
14
29
736
112
29
-49
-29
-60
-35
Effective Tax Rate (%)
- -
22.66
13.86
20.47
28.83
28.14
19.72
19.88
19.95
15.38
- -
- -
- -
- -
Profit Margin (%)
2.32
4.89
7.67
4.39
1.72
1.75
3.66
28.14
11.42
5.08
-11.65
-6.8
-15.6
-8.61
Working Capital
377
619
501
481
474
457
459
1,062
820
795
707
654
583
573
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
461
709
740
686
670
666
659
1,347
1,068
1,022
926
866
794
787
Return on Invested Capital (%)
- -
3.81
7.63
5.71
3.44
1.13
3.66
70.77
9.2
-1.2
- -
- -
- -
- -
Return on Capital (%)
- -
6.26
9.69
5.1
1.96
2.13
4.34
73.43
9.32
2.74
- -
- -
- -
- -
Return on Common Equity (%)
3.42
6.2
9.69
5.1
1.96
2.13
4.34
73.43
9.32
2.74
-5.01
-3.19
-7.28
-4.49

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
843
814
788

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
650
652
645
Cash, Cash Equivalents & STI
144
109
116
Accounts Receivable, Net
42
55
51
Inventories
441
462
457
Total Current Liabilities
67
73
72
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.39%
-9.84%
-8.33%
Free Cash Flow
951.4%
-140.05%
-175.02%
Net Income, GAAP
209.81%
-71.85%
111.53%
Sales/Revenue/Turnover
8.07%
-27.65%
-7.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
88
106
107
119
421
2025
92
101
101
94
388
2026
93
121
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.24
-0.08
-0.18
-0.11
-0.6
2025
-0.4
-0.47
-0.23
-0.16
-1.27
2026
-0.26
-0.09
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.91
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yue Chien Huang
Full Time Employees
300
Sector
Electronic technology
Industry
Electronic equipment/Instruments
Address
No. 3, Industrial East 9th Road Hsinchu TP Taiwan 300
IPO Date
Oct 12, 2004
Business
Radiant Innovation Inc. (3373.TWO) designs, manufactures, and sells infrared technology products focused on temperature measurement and air quality monitoring in Taiwan. The company offers medical infrared thermometers, including infrared ear thermometers, non-contact forehead thermometers, and multi-function thermometers; industrial non-contact infrared thermometers and laser infrared thermometers; CO2 monitors and detectors; probe covers; and wearable CO2 detectors with metronome functionality such as the ZGM01 model. Founded in 2000 and headquartered in Hsinchu City, Taiwan, Radiant Innovation operates primarily in the healthcare and industrial sectors, serving medical, consumer, and professional markets with products certified to ISO 9001, ISO 13485, CE, FDA, and ASTM standards; it maintains a complete in-house supply chain for research, development, quality assurance, and manufacturing. The company participates in global exhibitions such as MEDICA 2025 in Düsseldorf, Germany, and continues to innovate in infrared system-on-chip (IR-SoC) technology without reported major acquisitions, partnerships, funding rounds, or strategic shifts in the last 1-2 years.